Healing Potentiality of Trypsin and Alpha Chemo Trypsin in Mandibular Molars With Chronic Apical Abscess

Study Overview
=================
Brief Summary
-----------------
assessment of healing potentiality of peri apical lesions using different doses of trypsin and alpha chemo trypsin in mandibular molars with chronic apical abscess

Detailed Description
-----------------
Owing to anti-inflammatory, anti-oedematous, fibrinolytic, anti-infective, and analgesic effects, trypsin: chymotrypsin oral combination has emerged as a promising treatment of mandibular molars with chronic apical abscess. Trypsin chymotrypsin combination always showed a significant reduction in swelling and pain postoperatively. Study procedures: According to inclusion and exclusion criteria; patients will be subjected to complete history taking, general and local dental examinations. Important dental symptoms will be assessed include bleeding, pain, malocclusion, new growths, numbness or paresthesias, and chewing problems. General information will be reported including use of alcohol or tobacco and systemic symptoms, such as fever and weight loss. A thorough inspection with good illumination, a tongue blade, gloves, and a gauze pad will be performed. Complete or partial dentures will be removed so that underlying soft tissues can be seen. A head-mounted light will be used. However, because the light cannot be precisely aligned on the axis of vision, it is difficult to avoid shadowing in narrow areas. Better illumination results will be performed with a head-mounted convex mirror. The temporomandibular joint (TMJ) will be assessed by looking for jaw deviation on opening and by palpating the head of the condyle anterior to the external auditory meatus. Examiner then place his little fingers into the external ear canals with the pads of the fingertips lightly pushing anteriorly while patients repeatedly open widely and then close. Preoperative preapical X-ray and CBCT will be done. Cases will be randomly divided into 3 groups; Group A will receive (Alphintern®, tablet, Amoun, Egypt), Group B will receive (Limitless Allzyme Max®, tablet, Eva, Egypt) Group C will not receive medication Medications will be taken three times daily for 7 days postoperative, after that all cases will be reexamined regarding healing rate, adverse effect and failure rate of medical treatment. Randomization, allocation and concealment: It will be done using computer generated randomization sheet. Sealed opaque packages will be given to a third person (nurse) who will assign the packages to study groups. Each patient will be invited to pull out a package. According to the number inside package, cases will be allocated to either group A, B or C according to a computer- generated random list. Postoperative preapical X-ray will be done at the end of the root canal treatment. Patient will be recalled after three months for preapical X-ray assessment. After six months patient will be recalled for preapical X-ray and CBCT to be done.

Official Title
-----------------
Healing Potentiality of Different Doses of Trypsin and Alpha Chemo Trypsin in Mandibular Molars With Chronic Apical Abscess

Conditions
-----------------
Mandibular Abscess

Intervention / Treatment
-----------------
* Drug: Alphintern® , tablet, Amoun, Egypt


Participation Criteria
=================
Eligibility Criteria
-----------------
Inclusion Criteria: Age: any age group. Both genders. Cases with mandibular molars with chronic apical abscess Exclusion Criteria: Patients with significant comorbidities like uncontrolled diabetes mellitus, hypertension, hepatic or renal disorders. Immunocompromised patients. Patient with allergy from study medications.
Sexes Eligible for Study
-----------------
All

Accepts Healthy Volunteers
-----------------
No

Study Plan
=================
How is the study designed?
-----------------

Design Details

Primary Purpose: Treatment
Allocation: Randomized
Intervention Model: Parallel Assignment
Masking: Double


Arms and Interventions

| Participant Group/Arm | Intervention/Treatment |
| --- | --- |
| Active Comparator: Alphintern<br>Group A will receive (Alphintern® tablet, Amoun, Egypt), | Drug: Alphintern® , tablet, Amoun, Egypt<br>* Medications will be taken three times daily for 7 days postoperative, after that all cases will be reexamined regarding healing rate, adverse effect and failure rate of medical treatment.<br>* Other names: Limitless Allzyme Max®, tablet, Eva, Egypt;|
| Active Comparator: Alzyme Max<br>Group B will receive (Limitless Allzyme Max®, tablet, Eva, Egypt) | Drug: Alphintern® , tablet, Amoun, Egypt<br>* Medications will be taken three times daily for 7 days postoperative, after that all cases will be reexamined regarding healing rate, adverse effect and failure rate of medical treatment.<br>* Other names: Limitless Allzyme Max®, tablet, Eva, Egypt;|
| No Intervention: Placebo<br>Group C will not receive medication | |

What is the study measuring?
-----------------
Primary Outcome Measures

| Outcome Measure | Measure Description | Time Frame |
| --- | --- | --- |
| Lesion size and bone Formation will be measured by cone-beam computed tomography | cone-beam computed tomography will be done Before Drug is given and after 6 months | 6 months |